Related Experiment Videos
Trandolapril in left ventricular dysfunction after myocardial infarction: focus on the TRACE study
1Unitat d'Hypertensió, Hospital Clinic, Instituto de Investigaciones Biomédicas Augusto Pi Suñer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Drugs of Today (Barcelona, Spain : 1998)
|April 2, 2003
Summary
Trandolapril, an angiotensin-converting enzyme (ACE) inhibitor, effectively lowers blood pressure and reduces cardiac strain in hypertensive patients. Clinical trials show it improves outcomes for heart failure patients post-myocardial infarction.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Clinical Therapeutics
Background:
- Trandolapril is a novel angiotensin-converting enzyme (ACE) inhibitor.
- Its active metabolite, trandolaprilat, exhibits high affinity for ACE.
- Trandolapril possesses potent ACE inhibition, a long plasma half-life, and significant lipophilicity.
Purpose of the Study:
- To evaluate the pharmacological and clinical efficacy of trandolapril.
- To assess trandolapril's effects on blood pressure and left ventricular hypertrophy in hypertensive patients.
- To determine the impact of trandolapril on mortality and life expectancy in patients with left ventricular dysfunction post-myocardial infarction.
Main Methods:
- Pharmacological profiling of trandolapril and its active metabolite.
- Clinical trials involving patients with mild-to-moderate hypertension and congestive heart failure.
- Analysis of blood pressure reduction ratios and combination therapy effects.
- Evaluation of data from the TRACE trial for mortality and survival outcomes.
Main Results:
- Trandolapril demonstrated potent ACE inhibition and a favorable pharmacokinetic profile.
- Once-daily trandolapril significantly reduced blood pressure and left ventricular hypertrophy in hypertensive patients.
- Trandolapril achieved a mean trough:peak ratio of blood pressure reduction over 50% with once-daily dosing.
- Combination therapy with verapamil enhanced blood pressure reduction in hypertensive individuals.
- The TRACE trial indicated reduced mortality and increased life expectancy with trandolapril in post-myocardial infarction patients with left ventricular dysfunction.
Conclusions:
- Trandolapril is an effective ACE inhibitor for managing hypertension and improving cardiovascular outcomes.
- Its long duration of action and efficacy in reducing cardiac remodeling are clinically significant.
- Trandolapril offers a valuable therapeutic option for patients with heart failure and hypertension.